Powder: -20°C for 3 years | In solvent: -80°C for 1 year
LY2795050 is a novel specific κ-Opioid Receptor antagonist (IC50: 0.72 nM).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 80.00 | |
2 mg | In stock | $ 117.00 | |
5 mg | In stock | $ 197.00 | |
10 mg | In stock | $ 317.00 | |
25 mg | In stock | $ 522.00 | |
50 mg | In stock | $ 747.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 216.00 |
Description | LY2795050 is a novel specific κ-Opioid Receptor antagonist (IC50: 0.72 nM). |
Targets&IC50 | κ-opioid Receptor:0.72 nM |
In vitro | LY2795050 displays full antagonist activity and high binding affinity and selectivity for κ-opioid Receptor (Ki: 0.72 nM) [1]. |
In vivo | In the brain, (11)C-LY2795050 displayed fast uptake kinetics (regional activity peak times of <20 min) and an uptake pattern consistent with the distribution of κ-Opioid Receptor (KOR) in primates [1]. The LY2795050 ED50 at MOR was 119 μg/kg based on a 1-site model for 11C-carfentanil. The 1-site binding model was also deemed sufficient to describe the specific binding of 11C-LY2795050 at KOR. The ED50 at KOR estimated from the 1-site model was 15.6 μg/kg. Thus, the ED50 ratio for MOR:KOR was 7.6 [2]. |
Molecular Weight | 407.89 |
Formula | C23H22ClN3O2 |
CAS No. | 1346133-08-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (122.58 mM), sonification is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
LY2795050 1346133-08-1 Endocrinology/Hormones GPCR/G Protein Neuroscience Opioid Receptor Inhibitor LY 2795050 central nervous system dysfunction sex differences inhibit κκ-receptor LY-2795050 inhibitor